BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17043625)

  • 1. Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy.
    Pelosi G; Volante M; Papotti M; Sonzogni A; Masullo M; Viale G
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):272-87. PubMed ID: 17043625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids.
    Naraev BG; Ramirez RA; Kendi AT; Halfdanarson TR
    Clin Lung Cancer; 2019 May; 20(3):e376-e392. PubMed ID: 30910575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candidates for peptide receptor radiotherapy today and in the future.
    Reubi JC; Mäcke HR; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():67S-75S. PubMed ID: 15653654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
    de Visser M; Verwijnen SM; de Jong M
    Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging tumors with peptide-based radioligands.
    Behr TM; Gotthardt M; Barth A; Béhé M
    Q J Nucl Med; 2001 Jun; 45(2):189-200. PubMed ID: 11476170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic applications of radiolabeled peptides in nuclear endocrinology.
    Behr TM; Béhé M; Becker W
    Q J Nucl Med; 1999 Sep; 43(3):268-80. PubMed ID: 10568142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lutetium-177-labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy.
    Panigone S; Nunn AD
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):310-21. PubMed ID: 17043628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in the expression of p53, KLF4, and p21 in neuroendocrine lung tumors.
    Naranjo Gómez JM; Bernal JF; Arranz PG; Fernández SL; Roman JJ
    Arch Pathol Lab Med; 2014 Jul; 138(7):936-42. PubMed ID: 24978920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment].
    Langfort R; Rudziński P; Burakowska B
    Pneumonol Alergol Pol; 2010; 78(1):33-46. PubMed ID: 20162517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.
    Reubi JC; Waser B
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):781-93. PubMed ID: 12707737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.
    Lo Russo G; Pusceddu S; Prinzi N; Imbimbo M; Proto C; Signorelli D; Vitali M; Ganzinelli M; Maccauro M; Buzzoni R; Seregni E; de Braud F; Garassino MC
    Tumour Biol; 2016 Oct; 37(10):12991-13003. PubMed ID: 27460087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT)].
    Papamichail DG; Exadaktylou PE; Chatzipavlidou VD
    Hell J Nucl Med; 2016; 19(1):75-82. PubMed ID: 27035909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor-mediated tumor targeting with radiolabeled peptides: there is more to it than somatostatin analogs.
    Mariani G; Erba PA; Signore A
    J Nucl Med; 2006 Dec; 47(12):1904-7. PubMed ID: 17138731
    [No Abstract]   [Full Text] [Related]  

  • 14. Systemic therapy for pulmonary carcinoids.
    Marquez-Medina D; Popat S
    Lung Cancer; 2015 Nov; 90(2):139-47. PubMed ID: 26371699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment.
    Reubi JC
    Neuroendocrinology; 2004; 80 Suppl 1():51-6. PubMed ID: 15477718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional imaging evaluation in the detection, diagnosis, and histologic differentiation of pulmonary neuroendocrine tumors.
    Lococo F; Treglia G; Cesario A; Paci M; Filice A; Versari A; Filosso PL
    Thorac Surg Clin; 2014 Aug; 24(3):285-92. PubMed ID: 25065929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors.
    Bombardieri E; Seregni E; Villano C; Chiti A; Bajetta E
    Q J Nucl Med Mol Imaging; 2004 Jun; 48(2):150-63. PubMed ID: 15243410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide receptors as molecular targets for cancer diagnosis and therapy.
    Reubi JC
    Endocr Rev; 2003 Aug; 24(4):389-427. PubMed ID: 12920149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.
    van Vliet EI; Teunissen JJ; Kam BL; de Jong M; Krenning EP; Kwekkeboom DJ
    Neuroendocrinology; 2013; 97(1):74-85. PubMed ID: 22237390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.